Literature DB >> 15058804

Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy.

Andrea Tramarin1, Nicoletta Parise, Stefano Campostrini, Donald D Yin, Maarten J Postma, Ramon Lyu, Roberta Grisetti, Amedeo Capetti, Anna Maria Cattelan, Maria Teresa Di Toro, Antonio Mastroianni, Elena Pignattari, Valeria Mondardini, Guido Calleri, Enzo Raise, Fabrizio Starace.   

Abstract

Diarrhea is a common symptom that many HIV patients experience either as a consequence of HIV infection or of highly active antiretroviral therapy (HAART). A multicenter, prospective observational study was conducted in 11 AIDS clinics in Italy to determine the effect of diarrhea on health-related quality of life among patients receiving HAART. The study enrolled 100 consecutive HIV positive patients who had diarrhea while on HAART. For each enrolled patient a control patient with matching disease stage who did not have diarrhea was identified using existing data from another prospective observational study conducted in 34 AIDS clinics (including the 11 in current study). Quality of life was measured by MOS-HIV Health Survey (MOS-HIV). Paired t-test and multiple regression analysis were used to compare the quality of life among patients with and without diarrhea. Mean patient age was 40 +/- 7 years; 69% were male. Mean CD4 cell count was 342 +/- 239 cells/mm3; 59% had AIDS. Of the cases, 49 patients had severe diarrhea (> 5 bowel movements or > 3 watery per day) and 46 patients had moderate diarrhea (3-5 bowel movements). Compared to matched control patients, cases experiencing diarrhea while on HAART had significantly lower MOS-HIV scores in all domains. The significant adverse effect of diarrhea on quality of life should be considered when choosing the appropriate antiretroviral drugs regimen.

Entities:  

Mesh:

Year:  2004        PMID: 15058804     DOI: 10.1023/B:QURE.0000015282.24774.36

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  22 in total

Review 1.  Cost effectiveness of combination HIV therapy: 3 years later.

Authors:  R D Moore
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

2.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1997-06-25       Impact factor: 56.272

3.  Pharmacoeconomic evaluation of intensified antiretroviral treatment strategies in HIV/AIDS.

Authors:  J M Bos; L T Berg; M J Postma
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2001-10       Impact factor: 2.217

4.  Why we need observational studies to evaluate the effectiveness of health care.

Authors:  N Black
Journal:  BMJ       Date:  1996-05-11

5.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

6.  Impact of diarrhoea and faecal incontinence on the daily life of HIV-infected patients.

Authors:  F Snijders; J B de Boer; B Steenbergen; M Schouten; S A Danner; F S van Dam
Journal:  AIDS Care       Date:  1998-10

7.  Quality of life and health service use among HIV-infected patients with chronic diarrhea.

Authors:  D P Lubeck; C L Bennett; P D Mazonson; S K Fifer; J F Fries
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-05

8.  Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors:  A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

9.  A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection.

Authors:  A W Wu; H R Rubin; W C Mathews; J E Ware; L T Brysk; W D Hardy; S A Bozzette; S A Spector; D D Richman
Journal:  Med Care       Date:  1991-08       Impact factor: 2.983

10.  Diarrhea and quality of life in ambulatory HIV-infected patients.

Authors:  A Watson; M H Samore; C A Wanke
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

View more
  13 in total

Review 1.  Crofelemer: a review of its use in the management of non-infectious diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

2.  Assessing HIV and AIDS treatment safety and health-related quality of life among cohort of Malaysian patients: a discussion on methodological approach.

Authors:  Imran Ahmed Syed; Syed Azhar Syed Sulaiman; Mohammad Azmi Hassali; Christopher K C Lee
Journal:  Health Expect       Date:  2013-09-08       Impact factor: 3.377

3.  Functional and psychosocial impact of oral disorders and quality of life of people living with HIV/AIDS.

Authors:  Mânia de Quadros Coelho; Jairo Matozinhos Cordeiro; Andreia Maria Duarte Vargas; Andréa Maria Eleutério de Barros Lima Martins; Thalita Thyrza de Almeida Santa Rosa; Maria Inês Barreiros Senna; Raquel Conceição Ferreira
Journal:  Qual Life Res       Date:  2014-08-14       Impact factor: 4.147

4.  Sources of emotional distress associated with diarrhea among late middle-age and older HIV-infected adults.

Authors:  Karolynn Siegel; Eric W Schrimshaw; Courtney J Brown-Bradley; Helen-Maria Lekas
Journal:  J Pain Symptom Manage       Date:  2010-06-25       Impact factor: 3.612

5.  Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.

Authors:  Anita J Brogan; Erik Smets; Josephine A Mauskopf; Sarah A L Manuel; Ines Adriaenssen
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

Review 6.  Health-related quality of life assessment after antiretroviral therapy: a review of the literature.

Authors:  Harleen Gakhar; Amanda Kamali; Mark Holodniy
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

7.  Protective effects of alanyl-glutamine supplementation against nelfinavir-induced epithelial impairment in IEC-6 cells and in mouse intestinal mucosa.

Authors:  Manuel B Braga-Neto; Bruna M C Oliveira; Raphael S Rodrigues; Francisco J Noronha; Renata F Leitao; Gerly A C Brito; Aldo A Lima; Richard L Guerrant; Cirle A Warren
Journal:  Cancer Biol Ther       Date:  2012-09-17       Impact factor: 4.742

8.  A new drug delivery system targeting ileal epithelial cells induced electrogenic sodium absorption: possible promotion of intestinal adaptation.

Authors:  Sho Haneda; Kouhei Fukushima; Yuji Funayama; Chikashi Shibata; Ken-Ichi Takahashi; Yasuhiko Tabata; Iwao Sasaki
Journal:  J Gastrointest Surg       Date:  2007-05       Impact factor: 3.452

9.  Diarrhea in patients with AIDS.

Authors:  Susan C Morpeth; Nathan M Thielman
Journal:  Curr Treat Options Gastroenterol       Date:  2006-02

10.  Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.

Authors:  Manuel B Braga Neto; Carolina V Aguiar; Jamilly G Maciel; Bruna M C Oliveira; Jesus E Sevilleja; Reinaldo B Oriá; Gerly A C Brito; Cirle A Warren; Richard L Guerrant; Aldo A M Lima
Journal:  BMC Gastroenterol       Date:  2010-08-11       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.